Demand in the U.K. is set to increase at a CAGR of 9.8% in the Europe meningococcal vaccines market during the forecast period. Expansion of product indications, and increasing pharmacy-based immunization services, are some of the key trends being witnessed in this marketplace

NEWARK, Del, Dec. 05, 2022 (GLOBE NEWSWIRE) -- The global meningococcal vaccines market stands at US$ 3.4 Bn as of now and is expected to reach US$ 7.7 Bn by the year 2032 at a CAGR of 8.6% between 2022 and 2032.

Vaccines that are into targeting some meningococcus strains like A, B, C, W-135, and Y are being made available. It is a known fact that vaccines enhance immunity levels by 80-100% for 2 years, with some of them needing booster doses. Plus, with spike in travel vaccine and enclosure of National Immunization Programs all over, the meningococcal vaccines market is expected to grow on an unstoppable note in the near future.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1252

The present scenario is such that resistance to antibiotics is rising. This is evident from the fact that various clonal complexes of Neisseria meningitidis like CC11 and CC4821 are exhibiting resistance with respect to antibiotics. This is another factor fostering continued research regarding meningococcal vaccines.

At the same time, the fact that there is stringency regarding regulatory guidelines as far as approval of vaccines is concerned can’t be ignored. Some of the leading bodies involved in approval of vaccines include EMA (European Medicines Agency) and the US FDA. Plus, these guideless are not in uniformity all over. These factors are likely to hamper the meningococcal vaccines market in the near future.

Apart from polysaccharides and conjugates, subcapsular vaccines are being discussed these days. They combine the advantages offered by both of them. As such, a mixed bag is always good to opt for. Future Market Insights has entailed these facts with future courses of action in its latest market study entitled ‘Meningococcal Vaccines Market’. The immaculate team of analysts and consultants has gone for bottom-up approach in this regard.

Key Takeaways from Meningococcal Vaccines Market

• North America holds the largest market share. This could be attributed to well-established healthcare infrastructure along with rise in awareness campaigns regarding meningococcal vaccines. On these grounds, GlaxoSmithKline, in August 2021, came up with ASK2BSure campaign to encourage parents to check with doctors to get their children vaccinated against meningitis B.

• Europe stands second on this count and would continue with its winning streak in the upcoming period. As per the European Centre for Disease Prevention and Control, IMD (Invasive Meningococcal Disease) is amongst the leading causes of septicemia and meningitis, with close to 200K cases witnessed every single year. There are European countries planning meningococcal vaccination programs.

• The Asia-Pacific is expected to grow at the fastest rate in the meningococcal vaccines market in the near future. This could be credited to initiatives taken by the governments regarding preventing the further prevalence of meningitis.
  
  

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1252

Competitive Analysis

• GlaxoSmithKline plc, in August 2020, started with patient dosing in phase III clinical study, wherein it compared 5-in-1 meningitis (MenABCWY) vaccine candidate against Menveo and Bexsero (licensed meningococcal vaccines.

• The EC (European Commission), in November 2020, authorized MenQuadfi to actively vaccinate people aged 12 and above against meningococcal illnesses caused due to Neisseria meningitis serogroups A, C, W, and Y.

• Pfizer Inc., in June 2020, began Phase III clinical trials pertaining to PF-06886992. It’s a pentavalent meningococcal vaccine candidate (MenABCWY).

• Bio-Manguinhos, in May 2021, inked an agreement with Emergex (UK) with the objective of establishing framework for subsequent clinical trials for producing meningococcal vaccine, Covid-19 vaccine, distribution, and marketing within Brazil.

• GlaxoSmithKline, in May 2022, did announce that it would pay nearly US$ 3.3 Bn for acquiring Affinivax for bolstering the vaccines’ pipeline.

• The University of Maryland School of Medicine (UMSOM), in March 2022, started leading research for assessing meningococcal vaccine for young children and infants in Africa.

“With growing occurrences of meningitis all over, the global meningococcal vaccines market is bound to witness an escalation in the near future”, says an analyst from Future Market Insights.

How inclusive is the Report?

• The research study is based on product (polysaccharide and conjugate), by age group (infants, children, adolescents & young adults, and adults), and by distribution channel (pharmacies, community clinics, public health agencies, and others (like hospital pharmacies).

• With growing programs of immunization and extensive research conducted regarding meningococcal vaccines, the global meningococcal vaccines market is bound to substantiate in the forecast period.

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-1252

Key Market Segments Covered in Meningococcal Vaccines Industry Research

By Product:

• Polysaccharide

• Conjugate
  

By Age Group:

• Infants

• Children

• Adolescents & young Adults

• Adults
  

By Distribution Channel:

• Pharmacies

• Community Clinics

• Public Health Agencies

• Others (hospital pharmacy, private market etc.)

Table of Content

1. Executive Summary

  1.1. Global Market Outlook

  1.2. Analysis and Recommendations

2. Market Overview

  2.1. Market Coverage / Taxonomy

  2.2. Market Definition / Scope / Limitations

3. Key Market Trends

  3.1. Key Trends Impacting the Market

4. Key Success Factors

  4.1. Disease Epidemiology

  4.2. Pipeline Assessment

  4.3. Parent Market Analysis

Complete TOC with Report Preview: https://www.futuremarketinsights.com/reports/meningococcal-vaccines-market

More Trending Reports by Future Market Research:

Spinal Fusion Market Size : The global spinal fusion market is expected to reach a valuation of US$ 9.49 Bn by the end of 2022. The market is set to further expand at a CAGR of 5.5% from 2022 to 2032.

Dermal Fillers Market Demand : Dermal Fillers Market is projected to exhibit 2.9% CAGR between 2021 and 2031.

Drug of Abuse Testing Market Value : Newly released data by Future Market Insights (FMI) shows that the global drug of abuse testing market is projected to reach a valuation of US$ 1.5 Bn in 2021, with sales growing at above 5% CAGR through 2031.

Laparoscopic Devices Market Trends : Expanding at a CAGR of 5.8%, the global Laparoscopic devices market is anticipated to increase from a valuation of US$ 12.3 Bn in 2022 to US$ 18.4 Bn by 2029.

Enzyme Replacement Therapy Market Forecast : The global enzyme replacement therapy market is expected to be worth US$ 9.3 Billion in 2022, with a CAGR of 6.7% to reach US$ 13.8 Billion by the end of 2028.

About Future Market Insights, Inc.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.  
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA  
T: +1-845-579-5705  
For Sales Enquiries: sales@futuremarketinsights.com